Department of Hematology and Coagulation, Sahlgrenska University Hospital, Göteborg, Sweden.
Bone Marrow Transplant. 2011 Jun;46(6):870-5. doi: 10.1038/bmt.2010.238. Epub 2010 Oct 18.
Allogeneic transplantation after reduced intensity conditioning (allo-RIC) is a treatment option for patients with Hodgkin's lymphoma (HL) relapsing after autologous transplantation. In all, 23 adult patients with HL underwent allo-RIC in Sweden between 2000 and 2007. The median number of previous treatment lines was five and 20 patients (87%) were previously autografted. TRM at 100 days and at 1 year was 13 and 22% respectively. Acute GVHD grades II-IV developed in 7 out of 23 patients (30%) and chronic GVHD in 10 out of 20 patients at risk (50%). The OS and EFS at three years was 59 and 27%, respectively. Four patients (17%) developed post transplant lymphoproliferative disease (PTLD) after a median time of 55 days (range 38-95); two of these patients later died. The study confirmed that allo-RIC is feasible, but associated with a substantial relapse rate: only 20% of the patients were still alive 7 years after the transplant. A finding of high incidence of PTLD needs to be confirmed in a larger trial that includes patients with non-HL and CLL.
异基因移植后,减少强度调理(allo-RIC)是自体移植后复发的霍奇金淋巴瘤(HL)患者的一种治疗选择。在瑞典,2000 年至 2007 年间共有 23 名成人 HL 患者接受了 allo-RIC。之前治疗线的中位数为 5 条,20 名患者(87%)之前接受过自体移植。100 天和 1 年的 TRM 分别为 13%和 22%。23 名患者中有 7 名(30%)发生了 II-IV 级急性移植物抗宿主病,20 名有风险的患者中有 10 名(50%)发生了慢性移植物抗宿主病。3 年时的 OS 和 EFS 分别为 59%和 27%。4 名患者(17%)在中位时间为 55 天(范围为 38-95)后发生了移植后淋巴增殖性疾病(PTLD),其中 2 名患者后来死亡。该研究证实 allo-RIC 是可行的,但与较高的复发率相关:移植后 7 年,只有 20%的患者仍然存活。在一项包括非 HL 和 CLL 患者的更大试验中,需要确认 PTLD 的高发生率。